In previous research, the AKT inhibitors AZD6244 and GDC0914, which suppress the MEK–ERK and PI3K–AKT pathways, respectively, have been used in combination to cure aggressive thyroid cancers [21]. Here, AKT1 is linked to thyroid cancer.